# Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

> **NCT02486718** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 1280 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Cisplatin
- **DRUG:** Vinorelbine
- **DRUG:** Docetaxel
- **DRUG:** Gemcitabine
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT02486718
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-10-31
- **Primary completion:** 2024-01-26
- **Final completion:** 2027-08-31
- **Target enrollment:** 1280 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02486718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02486718, "Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02486718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*